- Home
- PIII vs DARE Comparison
PIII vs DARE Comparison
Compare PIII & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- DARE
- Stock Information
- Founded
- PIII 2015
- DARE 2015
- Country
- PIII United States
- DARE United States
- Employees
- PIII N/A
- DARE N/A
- Industry
- PIII Medical/Nursing Services
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- DARE Health Care
- Exchange
- PIII Nasdaq
- DARE Nasdaq
- Market Cap
- PIII 27.8M
- DARE 28.6M
- IPO Year
- PIII N/A
- DARE N/A
- Fundamental
- Price
- PIII $9.22
- DARE $2.10
- Analyst Decision
- PIII Strong Buy
- DARE Strong Buy
- Analyst Count
- PIII 3
- DARE 2
- Target Price
- PIII $17.50
- DARE $10.00
- AVG Volume (30 Days)
- PIII 5.1K
- DARE 203.8K
- Earning Date
- PIII 11-11-2025
- DARE 11-13-2025
- Dividend Yield
- PIII N/A
- DARE N/A
- EPS Growth
- PIII N/A
- DARE N/A
- EPS
- PIII N/A
- DARE N/A
- Revenue
- PIII $1,461,823,000.00
- DARE N/A
- Revenue This Year
- PIII N/A
- DARE $6,864.02
- Revenue Next Year
- PIII $10.45
- DARE $4,922.46
- P/E Ratio
- PIII N/A
- DARE N/A
- Revenue Growth
- PIII 4.20
- DARE N/A
- 52 Week Low
- PIII $5.80
- DARE $1.83
- 52 Week High
- PIII $24.73
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- PIII 54.75
- DARE 48.75
- Support Level
- PIII $8.65
- DARE $2.01
- Resistance Level
- PIII $9.29
- DARE $2.28
- Average True Range (ATR)
- PIII 0.40
- DARE 0.10
- MACD
- PIII -0.03
- DARE -0.01
- Stochastic Oscillator
- PIII 76.24
- DARE 35.71
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.